NovoCure (NVCR) Operating Leases (2019 - 2026)

NovoCure has disclosed Operating Leases across 8 years of filings, most recently posting $39.5 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $39.5 million, down 2.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.5 million (down 2.06% YoY), and the FY2025 annual result was $41.6 million, up 108.54% from the prior year.
• Operating Leases came in at $39.5 million for Q1 2026 at NovoCure, down from $41.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $42.9 million in Q2 2025 to a low of $13.4 million in Q2 2022.
• The 5-year median for Operating Leases is $21.7 million (2024), against an average of $26.3 million.
• Across the five-year window, Operating Leases fell 27.17% in 2024 and jumped 108.54% in 2025, its largest moves.
• NovoCure's Operating Leases stood at $18.8 million in 2022, then surged by 46.15% to $27.4 million in 2023, then dropped by 27.17% to $20.0 million in 2024, then surged by 108.54% to $41.6 million in 2025, then slipped by 5.21% to $39.5 million in 2026.
• The last three Operating Leases figures came in at $39.5 million (Q1 2026), $41.6 million (Q4 2025), and $42.7 million (Q3 2025), per Business Quant data.